Meissa Vaccines

Meissa Vaccines is a pharmaceutical development company focused on creating innovative vaccines for respiratory diseases. Based in San Francisco, California, the company specializes in developing vaccines for respiratory syncytial virus (RSV) and rhinovirus. Their primary mission is to reduce the burden of acute lower respiratory tract diseases, colds, and asthma, particularly in infants and young children.

The company has made significant strides in its vaccine development efforts, particularly with its pediatric RSV vaccine candidate. Meissa has reported positive clinical data for what they claim is the first RSV vaccine designed specifically to protect infants and toddlers. To support their progress, they have entered into a CGMP (Current Good Manufacturing Practice) manufacturing agreement, demonstrating their commitment to advancing their vaccine candidates towards potential market approval.